Santen Pharmaceutical Co (SNPHY) AI Stock Analysis

• Market Cap: $3.84B
• Dividend Yield: 2.02%
• Average Volume (3M): 1.01K
• Price to Earnings (P/E): 16.3
• Beta (1Y): 0.05
• Revenue Growth: -3.03%
• EPS Growth: 27.51%
• Country: US
• Employees: 3,744
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - General
• EPS (TTM): 0.16
• Shares Outstanding: 322,273,960
• 10 Day Avg. Volume: 2,904
• 30 Day Avg. Volume: 1,010
• PEG Ratio: 0.32
• Price to Book (P/B): 1.73
• Price to Sales (P/S): 1.65
• P/FCF Ratio: 9.12
• Enterprise Value/Market Cap: 153.22
• Enterprise Value/Revenue: 2.03
• Enterprise Value/Gross Profit: 3.66
• Enterprise Value/Ebitda: 9.54
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 65 Neutral
• Price Target: $12.00 ▲(9.09% Upside)
• Action: Reiterated Date: 02/08/26
• Date: Action: Reiterated 02/08/26

The score is primarily driven by financial performance: strong leverage profile and profitability are offset by a pronounced TTM revenue decline and softer cash-flow momentum. Technicals and valuation are both neutral-to-slightly positive, offering limited additional support.

Positive Factors

Conservative Balance Sheet

Santen’s low debt-to-equity (~0.13) and sizable equity base provide enduring financial flexibility. This conservative financing lowers refinancing risk, supports continued R&D and manufacturing investment, and creates capacity to absorb shocks or pursue strategic deals without levering up.

Negative Factors

Sharp Revenue Decline

A ~-74% TTM revenue contraction is a material structural headwind: it erodes market share, limits scale benefits, and undermines the sustainability of margins and R&D funding. Restoring top-line growth is essential for long-term earnings durability and competitive positioning.

Santen Pharmaceutical Co Business Overview & Revenue Model

Company Description

Santen Pharmaceutical Co., Ltd. researches and develops, manufactures, and markets pharmaceuticals and medical devices in Japan and internationally. It offers various pharmaceutical products to treat glaucoma and ocular hypertension, such as DE-11...

Read more

Santen Pharmaceutical Co., Ltd. researches and develops, manufactures, and markets pharmaceuticals and medical devices in Japan and internationally. It offers various pharmaceutical products to treat glaucoma and ocular hypertension, such as DE-11...

How the Company Makes Money

Santen Pharmaceutical generates revenue primarily through the sale of its ophthalmic products, which include prescription drugs, surgical devices, and consumer health products. The company's key revenue streams come from its portfolio of establish...

Read more

Santen Pharmaceutical generates revenue primarily through the sale of its ophthalmic products, which include prescription drugs, surgical devices, and consumer health products. The company's key revenue streams come from its portfolio of establish...

Santen Pharmaceutical Co Financial Statement Overview

Breakdown	TTM	Mar 2025	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Income Statement
Total Revenue	290.51B	300.00B	301.96B	279.04B	266.26B	249.60B
Gross Profit	160.92B	171.03B	178.71B	166.09B	156.59B	151.38B
EBITDA	61.76B	59.01B	50.72B	12.95B	52.93B	70.28B
Net Income	30.89B	36.26B	26.64B	-14.95B	27.22B	6.83B
Balance Sheet
Total Assets	401.43B	409.28B	435.70B	421.18B	459.98B	402.35B
Cash, Cash Equivalents and Short-Term Investments	61.59B	93.99B	94.96B	58.68B	84.31B	63.41B
Total Debt	36.17B	34.23B	35.16B	36.21B	32.93B	10.15B
Total Liabilities	118.81B	124.10B	130.33B	127.88B	123.13B	95.30B
Stockholders Equity	283.58B	286.24B	306.06B	293.98B	337.49B	307.58B
Cash Flow
Free Cash Flow	30.10B	54.27B	61.96B	12.56B	10.20B	15.00B
Operating Cash Flow	34.21B	60.93B	72.65B	37.15B	46.04B	38.81B
Investing Cash Flow	-10.60B	-8.22B	-6.14B	-26.78B	-35.17B	-53.35B
Financing Cash Flow	-34.15B	-53.31B	-34.03B	-37.22B	5.56B	-16.68B

Santen Pharmaceutical Co Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 11.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SNPHY, the sentiment is Positive. The current price of 11 is above the 20-day moving average (MA) of 10.88, above the 50-day MA of 10.98, and above the 200-day MA of 10.75, indicating a bullish trend. The MACD of 0.23 indicates Negative momentum. The RSI at 68.52 is Neutral, neither overbought nor oversold. The STOCH value of 93.40 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SNPHY.

Santen Pharmaceutical Co Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AZN	73 Outperform	£231.97B	28.13	23.00%	1.53%	10.20%	40.57%
BMY	71 Outperform	$117.44B	15.61	39.27%	4.11%	-0.22%	―
SNY	69 Neutral	$113.25B	-31.42	14.71%	4.58%	-9.32%	120.62%
GSK	67 Neutral	$112.33B	28.75	37.19%	3.41%	7.51%	132.14%
SNPHY	65 Neutral	$3.84B	16.26	10.88%	2.02%	-3.03%	27.51%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
GRFS	48 Neutral	$6.54B	14.03	7.56%	1.56%	9.45%	167.00%